Navigation Links
YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG
Date:10/29/2009

aggressive chemotherapy and radiotherapy by Wolff et al (J Neuro Oncology Vol. 79. #3, September 2006).

The multi-centre, open-label, single-arm study was completed in 2007 and designed to evaluate the effectiveness of nimotuzumab combined with radiation in children with newly diagnosed DIPG, an inoperable form of brain cancer for which treatment options are severely limited. The study enrolled 42 patients aged 3 to 16 years (median 7 years) between April 2006 and August 2007, with 41 patients evaluable for response. The primary endpoint is reported to be "probability of a patient surviving progression-free six months post-diagnosis or median PFS over six months" and secondary endpoints included overall survival, response rate, toxicity and quality of life. The principal investigator is Professor Udo Bode at the University of Bonn, Germany.

"Nimotuzumab continues to demonstrate efficacy in trials throughout the world while avoiding the severe toxicities of the currently available EGFR-targeting drugs," said David Allan, Chairman and CEO of YM BioSciences. "These results underscore the value of a drug that can deliver benefit while maintaining quality of life. Adding to the body of safety and efficacy data for nimotuzumab, 48-month survival data from the randomized 4-arm "BEST" trial will be presented at ASTRO 2009 which will permit reviewers to observe the activity and efficacy of nimotuzumab in the absence of the severe toxicities of the class."

YM is currently conducting a Phase II study in children suffering from recurrent DIPG at ten of the principal oncology hospitals in the US as well as sites in Canada and Israel, with data expected in 2010. The drug is available on a compassionate use basis in the US for children with pediatric glioma and is designated an Orphan Drug for adult and pediatric glioma by the FDA as well as the EMEA for Europe.

ASTRO Presentation

An oral presentation will be delivered at th
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  Health Enhancement Products, Inc. (OTCQB: ... early-stage algae bioactive compounds and metabolic processes, is pleased to ... board of directors. Ms. Nola E. Masterson , a ... joined the board effective September 17, 2014. ... to join our board," states Andrew Dahl , President ...
(Date:9/18/2014)... Research and Markets has ... Industry Report 2014" report to their offering. ... 2014 is a professional and in-depth study on ... The report provides a basic overview ... industry chain structure. The N-acetylcysteine market analysis is ...
(Date:9/18/2014)... -- MEI Pharma, Inc. (Nasdaq: MEIP ), an oncology ... cancer, announced today that Daniel P. Gold , Ph.D., ... NewsMakers in the Biotech Industry conference on Friday, September ... Broadway Hotel & Conference Center in New York ... accessed at www.meipharma.com . A replay will be available ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 OMICS ... the globe to participate in the ‘Open Access ... articles to OMICS Group Pharma Journals ... one of the fastest emerging Sciences, accelerating with ... healthcare services across the globe. The industry is ...
Breaking Biology Technology:Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Global N-acetylcysteine Industry Report 2014 2MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3
... - In order to enhance the worldwide launch of ... has formed a strategic marketing alliance with the globally operating ... food proof® range which has been available in almost ... new products will be launched jointly during the year 2008. ...
... VANCOUVER, April 18 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. ... global specialty pharmaceutical and,medical device company, today ... "BSC" (NYSE: BSX ) has received ... paclitaxel-eluting coronary stent system in Canada.,BSC reported ...
... 18 Cell Therapeutics, Inc.,(CTI) (Nasdaq and MTAX: CTIC) ... letter from The NASDAQ Stock Market indicating that for ... its common stock has closed,below the minimum $1.00 per ... notification has no immediate effect on,the listing of or ...
Cached Biology Technology:BIOTECON Diagnostics and MERCK KGaA start worldwide marketing alliance 2BIOTECON Diagnostics and MERCK KGaA start worldwide marketing alliance 3Angiotech's Corporate Partner, Boston Scientific, Reports Canadian Approval for TAXUS(R) Liberte(R) Stent System 2Angiotech's Corporate Partner, Boston Scientific, Reports Canadian Approval for TAXUS(R) Liberte(R) Stent System 3Angiotech's Corporate Partner, Boston Scientific, Reports Canadian Approval for TAXUS(R) Liberte(R) Stent System 4Cell Therapeutics, Inc. Announces Receipt of Letter From the NASDAQ Stock Market Regarding Non-Compliance With the Minimum Bid Price Requirement 2
(Date:9/18/2014)... researchers and their colleagues have built the first ... academic performance and behavioral trends. In other words, ... even if you don,t -- and how that ... students, happiness, stress, depression and loneliness to their ... general population for example, to monitor mental ...
(Date:9/18/2014)... algal forests in the eastern Mediterranean Sea pose a ... distribution continues to expand as the climate warms, a ... of researchers led by Dr Adriana Vergs of UNSW ... for Advanced Studies in Spain, is published in the ... surveyed more than 1000 kilometres of coastline in Turkey ...
(Date:9/18/2014)... camouflage: you don,t just blend in, the background shows ... as you might think. Kathryn Feller, from the University ... life stages of many marine species are transparent. However, ... creatures cannot make transparent. Feller explains that the animals ... unit with an opaque pigment to prevent light leaking ...
Breaking Biology News(10 mins):New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4Tropical fish a threat to Mediterranean Sea ecosystems 2Transparent larvae hide opaque eyes behind reflections 2
... substance found in red grapes and red wine, may have ... to a published laboratory study from Henry Ford Hospital in ... likely to suffer the long-term effects of noise-induced hearing loss ... a long period of time. "Our latest study focuses ...
... to become knotted, thus it may be useful to disentangle ... at random (or better, in one solution) the filaments with ... solutions like, for instance, having the DNA pass through nano-pores ... may exploit to selectively let a type of molecule pass ...
... struggling to collect and analyze millions of gigabytes of ... National Institutes of Health has launched a $700 million ... training future scientists to tap that gold mine of ... current edition of Chemical & Engineering News ...
Cached Biology News:Study: Resveratrol shows promise to protect hearing, cognition 2The nano-channel that disentangles knots 2